Fig. 2From: Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patientsResponses among patients with wild-type tumor KRAS exon 2, RAS, and RAS/PIK3CA/BRAF Back to article page